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We thank Dr Olschewski and colleagues for their interest in our 
article,1 and we appreciate their recapitulation of 2 key findings of our 
work: (1) the identification of increased atrial K2P3.1 (TASK-1) K+ 
channel expression, IK2P3.1 upregulation, and action potential shorten-
ing as substrate in patients with chronic atrial fibrillation (AF); and 
(2) the presentation of K2P3.1 current inhibition and resulting action 
potential prolongation as mechanism-based therapeutic paradigm in 
this subentity of the arrhythmia. Our study focused on the mechanis-
tic contribution of K2P3.1 channels to human atrial electrophysiology 
and action potential regulation, with particular emphasis on patho-
physiological dysregulation in AF. Based on mechanistic data pre-
sented in the study, functional correction of atrial ionic remodeling 
through the suppression of atrial K2P3.1 current emerged as a novel 
antiarrhythmic option for AF management.
We agree with Olschewski et al that efficacy and safety require 
in-depth preclinical evaluation before transfer of novel therapeutic 
principles into human application. In their letter, the authors high-
light their findings of K2P3.1 expression and functional significance 
in human pulmonary artery smooth muscle cells,2 corresponding 
to previous observations by our group.3 K2P3.1 current in human 
pulmonary artery smooth muscle cells regulates vascular tone and 
pulmonary arterial pressure, and IK2P3.1 reduction by endothelin-1 
or genetic mutations has been implicated in the pathophysiology of 
pulmonary arterial hypertension. To date, clinical data on in vivo 
application of specific K2P3.1 inhibitors in humans or large ani-
mals have not been reported. Thus, conclusions regarding the true 
extent and causal relations between systemic K2P3.1 blockade and 
potential effects on pulmonary vasculature are limited. Nonetheless, 
pulmonary vascular tone should be carefully considered in future 
studies addressing K2P3.1 as antiarrhythmic target. Similarly, cau-
tion is required regarding potential cardiac effects when direct or 
indirect pharmacological K2P3.1 activation is explored as therapeu-
tic principle in the treatment of pulmonary arterial hypertension. 
Increased K2P3.1 current amplitudes may result in atrial arrhythmia 
including AF, associated with further worsening of symptoms and 
prognosis.
Gene therapy with greater selectivity than small molecule-
based approaches may be used to exclude potential extracardiac 
side effects. The gene of interest is packaged into viral or nonviral 
carriers and delivered to the target area by means of direct injection 
or by use of catheter-based interventional techniques, providing the 
advantage of site-restricted action in contrast to systemic application 
of drugs. Previous studies confirmed effective use of gene therapeutic 
approaches targeting electric or structural substrates for rhythm con-
trol in large-animal models of AF.4,5 Similarly, a better understand-
ing of tissue-specific K2P3.1 channel regulation and of the molecular 
mechanisms underlying K2P3.1 upregulation might help to identify 
pathways to target increased atrial IK2P3.1 without affecting channels in 
human pulmonary artery smooth muscle cells.
In summary, K2P3.1 K+ channels are important for determining 
the action potential duration in human atrial myocytes,1 and they set 
the resting membrane potential and vascular tone in human pulmo-
nary artery smooth muscle cells.2,3 Further therapeutic exploitation 
of these significant mechanistic findings in cardiovascular medicine 
requires consideration of the potential side effects that may be mini-
mized by the choice of application mode, appropriate dose titration, 
thorough preclinical evaluation, and patient monitoring.
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